Autophagy in Plasma Cell Pathophysiology.
Oliva L et al. Front Immunol. 2014 Mar 12;5:103. eCollection 2014.

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Olsen OE et al. Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16.

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines.
Paíno T et al. PLoS One. 2014 Mar 21;9(3):e92378. doi: 10.1371/journal.pone.0092378. eCollection 2014.

Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: Relationship with bone disease and clinical characteristics.
Wang XT et al. Leuk Res. 2014 Mar 6. pii: S0145-2126(14)00059-9. doi: 10.1016/j.leukres.2014.02.010. [Epub ahead of print].

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Mithraprabhu S et al. Cell Death Dis. 2014 Mar 20;5:e1134. doi: 10.1038/cddis.2014.98.

PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells.
Medina EA et al. Leukemia. 2014 Mar 20. doi: 10.1038/leu.2014.112. [Epub ahead of print].

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
Tian E et al. Genes Chromosomes Cancer. 2014 Mar 17. doi: 10.1002/gcc.22165. [Epub ahead of print].

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.
Walker BA et al. Blood Cancer J. 2014 Mar 14;4:e191. doi: 10.1038/bcj.2014.13.

Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death.
Yin L et al. Blood. 2014 Mar 14. [Epub ahead of print].

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG et al. Semin Cancer Biol. 2014 Mar 11. pii: S1044-579X(14)00037-6. doi: 10.1016/j.semcancer.2014.03.001. [Epub ahead of print].

Autophagy, a new determinant of plasma cell differentiation and antibody responses.
Cenci S. Mol Immunol. 2014 Mar 10. pii: S0161-5890(14)00036-4. doi: 10.1016/j.molimm.2014.02.008. [Epub ahead of print].

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Tong Z et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):869-74. doi: 10.1007/s00280-014-2415-y. Epub 2014 Mar 14.

Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Hiraoka N et al. PLoS One. 2014 Mar 13;9(3):e90675. doi: 10.1371/journal.pone.0090675. eCollection 2014.

URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
Fan JL et al. Cell Death Dis. 2014 Mar 13;5:e1126. doi: 10.1038/cddis.2014.93.

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations.
Matarraz S et al. Leukemia. 2014 Mar 14. doi: 10.1038/leu.2014.103. [Epub ahead of print].

p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ et al. Leukemia. 2014 Mar 14. doi: 10.1038/leu.2014.102. [Epub ahead of print].

Auer rod-like inclusions in plasma cells in multiple myeloma.
Ho WK et al. J Clin Pathol. 2014 Mar 13. doi: 10.1136/jclinpath-2014-202195. [Epub ahead of print].

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.
Favaloro J et al. Leuk Lymphoma. 2014 Mar 14. [Epub ahead of print].

MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma.
Campo S et al. Br J Haematol. 2014 Mar 12. doi: 10.1111/bjh.12828. [Epub ahead of print].

The proteasome inhibitor bortezomib is a potent inducer of zinc-finger AN1-type domain 2a gene expression: role of HSF1/HSF2 heterocomplexes.
Rossi A et al. J Biol Chem. 2014 Mar 11. [Epub ahead of print].

Characterization of p38 MAPK Isoforms for Drug Resistance Study Using Systems Biology Approach.
Peng H et al. Bioinformatics. 2014 Mar 10. [Epub ahead of print].

Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.
Biran N et al. Am J Hematol. 2014 Mar 11. doi: 10.1002/ajh.23705. [Epub ahead of print].

A Nano Ultra-Performance Liquid Chromatography-High Resolution Mass Spectrometry Approach for Global Metabolomic Profiling and Case Study on Drug-Resistant Multiple Myeloma.
Jones DR et al. Anal Chem. 2014 Mar 20. [Epub ahead of print].

miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway.
Zhao JJ et al. Cancer Res. 2014 Mar 15;74(6):1801-13. doi: 10.1158/0008-5472.CAN-13-3311-T. Epub 2014 Mar 5.

Contributions of the host microenvironment to cancer-induced bone disease.
Olechnowicz SW et al. Cancer Res. 2014 Mar 15;74(6):1625-31. doi: 10.1158/0008-5472.CAN-13-2645. Epub 2014 Mar 5.

Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells.
Pei XY et al. PLoS One. 2014 Mar 4;9(3):e89064. doi: 10.1371/journal.pone.0089064. eCollection 2014.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
Hebraud B et al. Leukemia. 2014 Mar;28(3):726. doi: 10.1038/leu.2013.352.

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma.
Di Martino MT et al. PLoS One. 2014 Feb 27;9(2):e90005. doi: 10.1371/journal.pone.0090005. eCollection 2014.

Peptide-Based Proteasome Inhibitors in Anticancer Drug Design.
Micale N et al. Med Res Rev. 2014 Mar 1. doi: 10.1002/med.21312. [Epub ahead of print].

Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.
Kim GY et al. Genes Chromosomes Cancer. 2014 Mar 3. doi: 10.1002/gcc.22158. [Epub ahead of print].

Investigation of circulating lncRNAs in B-cell neoplasms.
Isin M et al. Clin Chim Acta. 2014 Feb 26;431C:255-259. doi: 10.1016/j.cca.2014.02.010. [Epub ahead of print].

Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.
García-Castillo H et al. Med Oncol. 2014 Apr;31(4):900. doi: 10.1007/s12032-014-0900-0. Epub 2014 Mar 1.

Central nervous system multiple myeloma: a different cytogenetic profile.
Gozzetti A et al. Br J Haematol. 2014 Feb 26. doi: 10.1111/bjh.12812. [Epub ahead of print].

Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations–An Extensive Replication of the Associations from the Candidate Gene Era.
Martino A et al. Cancer Epidemiol Biomarkers Prev. 2014 Mar 11. [Epub ahead of print].

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers.
Garcia PD et al. Clin Cancer Res. 2014 Mar 13. [Epub ahead of print]